# Germany Pharmaceutical Drug Market

> Germany pharmaceutical drug market: USD 65.0 billion in 2025, up 3.12% a year to USD 88.3 billion by 2035 as ageing and biologics offset the 2027 15.5% rebate.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10762  
Published: 2026-10-23  
Last updated: 2026-10-23  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/germany-pharmaceutical-drug-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $65.0 Bn | 58.0 billion DDDs x USD 1.12 per dose = USD 65.0 billion (about EUR 57.5 billion). |
| Forecast · 2035 | $88.3 Bn | Base case: 0.70% volume and 2.40% price per dose a year. |
| Revenue CAGR · 2026–2035 | 3.12% | (1.0070 x 1.0240) minus 1. |
| Volume · 2035 | About 62.2 billion daily doses | Ageing, GLP-1 therapy and launches, less population decline. |
| Leading segment | Branded biologics, 35.0% | USD 22.7 billion in 2025 at about USD 26.1 per daily dose. |
| Fastest segment | Biosimilars, 9.00% | USD 3.90 billion to USD 9.23 billion as antibody copies follow adalimumab. |
| Fastest region | Bavaria, 3.45% | USD 10.1 billion to USD 14.1 billion; growing population and early oncology prescribing. |
| Market leader | Novartis, about 5.0% | Douglas Insights estimate from group filings; top three with Roche and Sanofi 13.4%. |
| Event | Bundestag passes rise in statutory manufacturer rebate from 7% to 15.5% from 2027 | Federal Ministry of Health, 10 July 2026. |

## Key takeaways

- The Germany pharmaceutical drug market is worth USD 65.0 billion in 2025 and USD 88.3 billion in 2035, a 3.12% revenue CAGR.
- Daily doses add 0.70% a year and price per dose 2.40%; the 15.5% rebate from 2027 removes 0.35 points a year from price.
- Branded biologics lead with 35.0% of value, while biosimilars grow fastest at 9.00% a year.
- North Rhine-Westphalia buys USD 14.3 billion, 22.0% of value, and Bavaria grows fastest at 3.45%.
- Announced German investment cuts by Lilly and Boehringer, EUR 2.05 billion, equal about one year of the new rebate.

The Bundestag passed the GKV-Beitragssatzstabilisierungsgesetz on 10 July 2026, raising the statutory manufacturer rebate on branded medicines from 7% to a fixed 15.5% and freezing prices of patent-protected vaccines from 1 January 2027 to 31 December 2030, according to the [Federal Ministry of Health (BMG)](https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026) and the [Deutsches Ärzteblatt](https://www.aerzteblatt.de/archiv/gkv-beitragsstabilisierungsgesetz-vielfaeltige-auswirkungen-a282b833-2a67-4626-970a-02d5a20c916e); Germany has chosen to buy the same medicines for less rather than fewer of them. The Germany pharmaceutical drug market covers finished prescription and over-the-counter medicines sold to patients, pharmacies and hospitals inside Germany, valued at manufacturer invoice prices; exports are excluded. Douglas Insights sizes it at USD 65.0 billion in 2025, about EUR 57.5 billion, from 58.0 billion defined daily doses (DDDs) at an average USD 1.12 per dose, and at USD 88.3 billion in 2035, a revenue CAGR (compound annual growth rate) of 3.12%. It is the German cut of our global [Pharmaceutical Drug Market](https://www.douglasinsights.com/pharmaceutical-drug-market/) report, sits in our [healthcare and life sciences coverage](https://www.douglasinsights.com/industry/healthcare/), and every figure follows the Douglas Insights [research methodology](https://www.douglasinsights.com/research-methodology/).

## Where does German pharmaceutical drug money go: biologics, patented pills, generics, OTC or biosimilars?

Branded biologics take most German pharmaceutical drug money, 35.0% of 2025 value, USD 22.7 billion, because antibodies and peptides cost about USD 26.1 per daily dose. Biosimilars grow fastest, 9.00% a year to USD 9.23 billion.

| Germany pharmaceutical drug segment | Share 2025 | Value 2025 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Branded biologics | 35.0% | USD 22.7 billion | 4.30% | USD 34.6 billion |
| Branded small molecules | 32.0% | USD 20.8 billion | 1.10% | USD 23.2 billion |
| Generics | 15.0% | USD 9.74 billion | 2.00% | USD 11.9 billion |
| Over-the-counter (OTC) medicines | 12.0% | USD 7.80 billion | 2.30% | USD 9.79 billion |
| Biosimilars | 6.0% | USD 3.90 billion | 9.00% | USD 9.23 billion |

Branded biologics, USD 22.7 billion, lead because oncology antibodies, immunology injectables and GLP-1 peptides carry the highest prices per dose in the German system, and new launches enter at a free price for the first six months before the AMNOG negotiated price applies. They grow 4.30% a year, slower than worldwide, because the higher rebate from 2027 bites hardest on exactly these products. Branded small molecules, USD 20.8 billion, grow only 1.10% a year: Bayer's anticoagulant Xarelto shows why, with first-quarter 2026 sales down 40.4% after patent expiries, according to [Bayer's results of 12 May 2026](https://www.bayer.com/media/en-us/2026-0082e/).

Generics, USD 9.74 billion, supply about 74% of German daily doses but only 15.0% of value, because sickness-fund rebate tenders and reference prices (Festbeträge) push prices to about USD 0.227 per dose; they grow 2.00% a year as Xarelto-type expiries move volume into this tier. OTC medicines, USD 7.80 billion, cover pharmacy-only self-medication such as pain relief and cough remedies that patients mostly pay themselves, and grow 2.30% a year. Biosimilars, USD 3.90 billion, grow fastest, 9.00% a year, as ustekinumab, aflibercept and denosumab copies follow adalimumab into German pharmacies. Segment values for 2035 sum to USD 88.7 billion, 0.48% above the headline.

The dose-value gap is the defining feature. A biologic dose costs about 115 times a generic dose, so a 1.5% share of doses yields 35.0% of value. That is why German cost control targets branded prices first, and why every policy change in this report acts on the price leg rather than on how many tablets Germans take.

## Why do Germans take more medicine each year while the population shrinks?

Ageing lifts German pharmaceutical drug volume 0.70% a year, from 58.0 billion daily doses in 2025 to 62.2 billion in 2035, even though the population fell 0.1% in 2025. Three drivers add 1.00 point before restraints.

Germany ended 2025 with about 83.5 million residents, 110,000 fewer than a year earlier, while people aged 60 and over rose by 387,000 to 31% of the population, the Federal Statistical Office (Destatis) reported on [16 June 2026](https://www.destatis.de/DE/Presse/Pressemitteilungen/2026/06/PD26_203_124.html). Deaths exceeded births by 352,000. Older patients take several daily medicines for decades, so a smaller but older Germany buys more doses.

### Ageing and chronic multimorbidity: 0.60 points

Ageing adds 0.60 points. Hypertension, diabetes, heart failure and chronic kidney disease are treated for life, and Bayer's Kerendia, up 84.2% in the first quarter of 2026 according to [Bayer](https://www.bayer.com/media/en-us/2026-0082e/), shows how new chronic-disease drugs add patients rather than replace pills.

### Obesity and diabetes therapy: 0.25 points

GLP-1 drugs add 0.25 points. Statutory insurance still excludes most weight-loss use, so volume rises through diabetes prescriptions and private purchase; Eli Lilly is still building an injectables plant in Alzey, Rhineland-Palatinate, due to open at the end of 2027, the [Pharmazeutische Zeitung reported](https://www.pharmazeutische-zeitung.de/lilly-werk-in-alzey-im-plan-167453/) on 10 August 2026.

### New therapies reaching patients: 0.15 points

Launches add 0.15 points. Germany is usually the first European market for a new drug because the free-pricing window lets it be sold from approval, so oncology and rare-disease patients are treated earlier than in France or Italy. The three drivers total 0.60 + 0.25 + 0.15 = 1.00 point.

The money follows the same patients. Statutory health insurance (GKV) drug spending rose 5.9%, or EUR 3.2 billion, in 2025, which implies about EUR 57.4 billion at pharmacy prices, while total GKV spending reached EUR 352.4 billion, the BMG said on [10 March 2026](https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/finanzentwicklung-gkv-2025). Hospital treatment rose faster, 9.6%, which is why the government looked to medicines for savings.

## What cuts German pharmaceutical drug growth: the 15.5% rebate, shortages or a shrinking population?

The 15.5% rebate cuts German pharmaceutical drug growth most: it removes 0.35 points a year from the price leg. Generic erosion takes 0.55 points of price, and a shrinking population and supply gaps 0.30 points of volume.

Volume restraints total 0.30 points, leaving 0.70% a year. Population decline removes 0.10 points, in line with the 0.1% fall in 2025. Supply gaps and delisting of non-prescription items from GKV cover remove 0.20 points, as patients pay for some remedies themselves and buy fewer.

The price leg starts from 3.30 points of mix and launch gains and loses 0.90 points: 0.55 from patent expiries such as Xarelto and 0.35 from the rebate step. The rebate on medicines without a reference price rises by 8.5 points in 2027 under the law the [Bundestag passed on 10 July 2026](https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026), and Douglas Insights estimates that drugs carrying that rebate hold about 42% of 2025 market value, USD 27.3 billion; the extra 8.5 points therefore cost manufacturers about USD 2.32 billion a year at 2025 values. Spread over the decade, that one-off step lowers the yearly price leg by 0.35 points.

The third restraint is investment. The rebate does not lower demand, but it changes where companies build: the Exclusive below sets the cuts announced since July 2026 against the rebate's yearly cost.

## Which German states spend most on medicines, and why does Bavaria grow fastest?

North Rhine-Westphalia spends most, USD 14.3 billion or 22.0% of 2025 German pharmaceutical drug value. Bavaria grows fastest, 3.45% a year to USD 14.1 billion by 2035, Douglas Insights estimates.

| State group | Value 2025 | Share 2025 | Value 2026 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- | --- |
| North Rhine-Westphalia | USD 14.3 billion | 22.0% | USD 14.7 billion | 3.00% | USD 19.2 billion |
| Eastern states and Berlin | USD 13.6 billion | 21.0% | USD 14.0 billion | 2.80% | USD 18.0 billion |
| Northern states (Lower Saxony, Hamburg, Bremen, Schleswig-Holstein) | USD 10.4 billion | 16.0% | USD 10.7 billion | 3.10% | USD 14.1 billion |
| Bavaria | USD 10.1 billion | 15.5% | USD 10.4 billion | 3.45% | USD 14.1 billion |
| Baden-Württemberg | USD 8.44 billion | 13.0% | USD 8.73 billion | 3.35% | USD 11.7 billion |
| Hesse, Rhineland-Palatinate and Saarland | USD 8.12 billion | 12.5% | USD 8.38 billion | 3.20% | USD 11.1 billion |

North Rhine-Westphalia leads because it holds about a fifth of Germany's residents and dense university hospitals in Cologne, Düsseldorf, Essen and Münster that prescribe specialty biologics. The eastern states and Berlin, USD 13.6 billion, spend more per person than their population share implies because Saxony, Saxony-Anhalt and Thuringia are the oldest parts of Germany, but they grow slowest, 2.80% a year, as their populations shrink.

Bavaria and Baden-Württemberg grow fastest, 3.45% and 3.35%, because both still gain residents and prescribe new oncology and immunology drugs early through Munich, Heidelberg and Freiburg cancer centres. The northern states, USD 10.4 billion, and the Hesse group, USD 8.12 billion, grow near the national rate. Regional values for 2035 sum to USD 88.3 billion, within 0.01% of the headline; in the data table the row labelled Global holds the Germany total, USD 65.0 billion in 2025.

## Who sells the most medicine in Germany: Novartis, Roche, Sanofi or the German makers?

Novartis sells the most medicine in Germany, about 5.0% of 2025 value, USD 3.25 billion, Douglas Insights estimates. With Roche and Sanofi, the top three hold only 13.4%, because no company leads more than a few therapy areas.

| Company | What the position rests on | Estimated share 2025 | Estimated value 2025 |
| --- | --- | --- | --- |
| Novartis (with Sandoz separate) | Entresto, Kesimpta, Cosentyx, Kisqali; German base in Nuremberg | 5.0% | USD 3.25 billion |
| Roche | Oncology antibodies, Ocrevus, Vabysmo; sites in Grenzach, Penzberg and Mannheim | 4.6% | USD 2.99 billion |
| Sanofi | Dupixent, insulins and vaccines; Frankfurt-Höchst production | 3.8% | USD 2.47 billion |
| Boehringer Ingelheim | Jardiance, Ofev, respiratory inhalers; headquarters in Ingelheim | 3.4% | USD 2.21 billion |
| Bayer | Xarelto, Eylea, Nubeqa, Kerendia; headquarters in Leverkusen | 3.2% | USD 2.08 billion |
| Sandoz (Hexal) | Generics and biosimilars from Holzkirchen | 3.0% | USD 1.95 billion |
| Teva (ratiopharm) | Generics brand from Ulm | 2.8% | USD 1.82 billion |
| Other companies | Merck KGaA, AbbVie, Pfizer, MSD, AstraZeneca, Eli Lilly, Novo Nordisk, STADA and others | 74.2% | USD 48.2 billion |

The shares are Douglas Insights estimates built from group filings, because no company reports German pharmaceutical sales on their own. Novartis reported 2025 net sales of USD 16.7 billion in Europe, up 8% in dollars and 4% at constant currencies, in its [fourth-quarter 2025 report](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000007/a260204-99_2.htm). Boehringer Ingelheim reported group sales of EUR 27.8 billion, up 7.3% at constant currency, with human pharma at EUR 22.733 billion and Europe at EUR 10.652 billion, in its [2025 annual report highlights](https://www.bayern.landtag.de/fileadmin/lobbyregister/DEBYLT03CD/Boehringer-Ingelheim-Geschaeftsbericht-Highlights-2025.pdf).

In generics, STADA reported 2025 group sales of EUR 4.296 billion, up 6%, with specialty products passing EUR 1 billion and a top-three position in German generics retail, in its [18 March 2026 results](https://www.stada.de/media/5jxj24un/20260318_pressemitte-ergebnisse-2025.pdf). The German generics trio of Hexal, ratiopharm and STADA competes for sickness-fund tenders on the same molecules, which keeps generic prices near USD 0.227 per dose. The same company ranking for the United States, where Medicare now negotiates prices, sits in our [U.S. Pharmaceutical Drug Market](https://www.douglasinsights.com/u-s-pharmaceutical-drug-market/) report.

## What does a daily dose cost in Germany, and why does the price leg still rise 2.40% a year?

A daily dose sold at USD 1.12 in Germany in 2025, Douglas Insights estimates, from USD 0.227 for a generic to USD 26.1 for a branded biologic. The average rises 2.40% a year to USD 1.42 by 2035.

| Price tier | Daily doses 2025 | Share of doses | Price per daily dose | Share of value |
| --- | --- | --- | --- | --- |
| Generics | 42.9 billion | 74.0% | USD 0.227 | 15.0% |
| OTC medicines | 6.96 billion | 12.0% | USD 1.12 | 12.0% |
| Branded small molecules | 6.67 billion | 11.5% | USD 3.12 | 32.0% |
| Biosimilars | 0.58 billion | 1.0% | USD 6.72 | 6.0% |
| Branded biologics | 0.87 billion | 1.5% | USD 26.1 | 35.0% |

Mix lifts the German pharmaceutical drug price per dose even when list prices fall. Patients move from tablets to injectables and from old classes to new ones, which adds 2.10 points a year; launch prices add 1.00 point and inflation adjustments 0.20 points. Patent expiries remove 0.55 points and the higher rebate 0.35 points, leaving 2.40%. Douglas Insights projects USD 1.15 per dose in 2026 and USD 1.42 in 2035.

Germany's average dose price is more than twice the USD 0.499 global average in our model and many times India's, as our [India Pharmaceutical Drug Market](https://www.douglasinsights.com/india-pharmaceutical-drug-market/) report shows, because Germany buys a richer mix of biologics. Amounts are converted at USD 1.13 per euro, the 2025 average of European Central Bank reference rates published by the [Bank of Finland](https://www.suomenpankki.fi/en/statistics/interest-rates-and-exchange-rates/exchange-rates/average-annual-exchange-rates-for-the-year-2025/).

## How do AMNOG, the 2027 rebate and the U.S. Section 301 probe change German drug pricing?

Three rules change German drug pricing: AMNOG benefit assessment and negotiated prices, the rebate rise from 7% to 15.5% in 2027, and a U.S. Section 301 investigation opened on 18 June 2026 into German pricing.

Under AMNOG, the Federal Joint Committee (G-BA) rates each new drug's added benefit and the GKV-Spitzenverband then negotiates a reimbursement price that applies after the launch period. The 2026 savings law adds a fixed 15.5% statutory rebate in place of a dynamic rebate that was dropped after industry criticism, a 9% extra rebate on patented vaccines and a vaccine price freeze referenced to the 1 June 2026 ex-factory price, with inflation compensation possible from 2028, the [Deutsches Ärzteblatt reported](https://www.aerzteblatt.de/archiv/gkv-beitragsstabilisierungsgesetz-vielfaeltige-auswirkungen-a282b833-2a67-4626-970a-02d5a20c916e). The BMG put the savings the whole law must deliver in 2027 at almost EUR 19 billion. A non-binding Bundestag resolution of 10 July 2026 asks for a site clause cutting the rebate for companies that enrol at least 5% of their global trial participants in Germany.

The Office of the U.S. Trade Representative (USTR) opened its investigation into Germany's "persistent underpayment" for innovative medicines on 18 June 2026, naming confidential-price discounts and variable rebates, with comments due on 10 August and a hearing on 22 September 2026, according to the [USTR announcement](https://ustr.gov/about/policy-offices/press-office/press-releases/2026/june/ustr-announces-initiation-section-301-investigation-germanys-persistent-underpayment-innovative). At EU level, the pharma package agreed on 11 December 2025 sets 8 years of data protection plus market protection, according to the [Council of the EU](https://www.consilium.europa.eu/en/press/press-releases/2025/12/11/pharma-package-council-and-parliament-reach-a-deal-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/), which shapes when German generics and biosimilars can launch.

## What if Berlin softens the rebate or the probe ends in tariffs: where does the German forecast land in 2035?

The Germany pharmaceutical drug market ends 2035 between USD 76.9 billion and USD 100 billion across our three cases, around a base of USD 88.3 billion. The rebate's final form and biologic uptake set most of the spread.

| Case | Volume leg | Price per dose leg | 2035 value |
| --- | --- | --- | --- |
| Slower | 0.30% | 1.40% | USD 76.9 billion |
| Base case | 0.70% | 2.40% | USD 88.3 billion |
| Faster | 1.10% | 3.30% | USD 100 billion |

In the slower case the 15.5% rebate stays without a site clause, more launches skip or delay Germany and the U.S. probe ends in tariffs on German exports that push companies to cut local supply. In the faster case the site clause cuts the rebate for companies that invest, GLP-1 cover widens and biosimilar savings are spent on new therapies. One extra point of yearly volume growth adds USD 9.17 billion to 2035 value; one point less removes USD 8.39 billion.

Our 3.12% base is below the 4.43% we use for Europe in the global model, because the 2027 rebate step is a German measure. Germany's share of European value therefore slips from 16.2% in 2025 to 14.3% in 2035.

## Douglas Exclusive: the Germany Rebate and Investment Ledger

The Germany Rebate and Investment Ledger is a Douglas Insights model built from 9 sourced inputs, 4 government releases, 3 company filings and 2 news reports, setting the 2027 rebate's yearly cost against the German investment cuts announced since.

| Date | Event | Value in the ledger |
| --- | --- | --- |
| 10 March 2026 | BMG reports GKV drug spending up 5.9% in 2025 | EUR 3.2 billion of added spending |
| 18 June 2026 | USTR opens Section 301 investigation into German pricing | Hearing on 22 September 2026 |
| 10 July 2026 | Bundestag passes rebate rise from 7% to 15.5% from 2027 | About EUR 2.05 billion a year, Douglas Insights estimate |
| 10 August 2026 | Eli Lilly cuts remaining Alzey plant scope by 50%, opening still end-2027 | About EUR 1.15 billion of a EUR 2.3 billion plan |
| By October 2026 | Boehringer Ingelheim cuts domestic spending | EUR 0.90 billion |
| 19 October 2026 | Roche puts all future German investment decisions on hold | EUR 3.8 billion invested since 2020 kept |

The Lilly cut was reported by the [Pharmazeutische Zeitung on 10 August 2026](https://www.pharmazeutische-zeitung.de/lilly-werk-in-alzey-im-plan-167453/), and the Roche pause and Boehringer cut by [Fierce Pharma on 19 October 2026](https://www.fiercepharma.com/pharma/roche-pauses-future-germany-investments-joining-growing-pharma-chorus). The finding, a Douglas Insights estimate: the extra 8.5 points of rebate cost manufacturers about EUR 2.05 billion a year, USD 2.32 billion, and the two quantified cuts, Lilly's EUR 1.15 billion and Boehringer's EUR 0.90 billion, also total EUR 2.05 billion. Industry has withdrawn about one year of the new rebate from German plants within three months of the vote, which is why the site clause, not the rebate rate, is the variable to watch for 2027 launches.

## How does the methodology turn 58.0 billion daily doses into USD 65.0 billion of German drug sales?

Our methodology multiplies 58.0 billion defined daily doses of medicine sold in Germany in 2025 by USD 1.12 per dose to reach USD 65.0 billion. Doses come from five price tiers; prices from rebates, filings and mix.

The model covers 6 state groups, 5 product segments, 3 channels and 5 price tiers, and uses 64 data points, 13 sourced and 51 modelled. Arithmetic: 58.0 billion x USD 1.12 = USD 64,960 million; 64,960 x (1.0070 x 1.0240)^10 = USD 88,295.8 million, or USD 88.3 billion. Doses reach 58.4 billion in 2026 and 62.2 billion in 2035. By channel, Douglas Insights estimates that retail pharmacy sells about 79% of value, hospital pharmacy about 18% and mail-order pharmacy about 3%.

Two cross-checks agree. First, USD 65.0 billion is 16.2% of the USD 401.3 billion Europe value in our global model, in line with Germany's place as Europe's largest drug market. Second, GKV pharmacy spending of about EUR 57.4 billion includes 19% VAT, pharmacy and wholesale margins, which our invoice-price basis excludes, while our EUR 57.5 billion adds hospital drugs, private insurance and self-paid OTC medicines; the two bases land close together. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our [editorial standards](https://www.douglasinsights.com/research-methodology/) explain.

## What counts as a German pharmaceutical drug sale here, and what stays out?

The Germany pharmaceutical drug market counts invoice-price sales of finished prescription and OTC medicines consumed in Germany, from domestic plants and imports. Exports, active ingredients, contract manufacturing, medical devices and dietary supplements stay out.

The by-product split covers branded biologics, branded small molecules, generics, OTC medicines and biosimilars. The by-channel split covers retail pharmacy, hospital pharmacy and mail-order pharmacy. The by-region split covers North Rhine-Westphalia, the eastern states and Berlin, the northern states, Bavaria, Baden-Württemberg, and Hesse with Rhineland-Palatinate and Saarland. Pharmacy margins, VAT and wholesale fees are excluded, as are medicines made in Germany and sold abroad, which are counted in their destination markets. Insulin, one of the largest biologics by dose, is sized in our [Insulin Drug Market](https://www.douglasinsights.com/insulin-drug-market/) report, and the Asia Pacific comparison sits in our [Asia Pacific Pharmaceutical Drug Market](https://www.douglasinsights.com/asia-pacific-pharmaceutical-drug-market/) report.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Branded biologics | 35% | $22.7 Bn |
| Branded small molecules | 32% | $20.8 Bn |
| Generics | 15% | $9.74 Bn |
| Over-the-counter medicines | 12% | $7.80 Bn |
| Biosimilars | 6% | $3.90 Bn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 64,960 | 66,984.7 | 88,295.8 | 3.12% |
| North Rhine-Westphalia | 14,291.2 | 14,719.9 | 19,206.2 | 3% |
| Eastern states and Berlin | 13,641.6 | 14,023.6 | 17,980.3 | 2.8% |
| Northern states | 10,393.6 | 10,715.8 | 14,104.3 | 3.1% |
| Bavaria | 10,068.8 | 10,416.2 | 14,134.6 | 3.45% |
| Baden-Württemberg | 8,444.8 | 8,727.7 | 11,740.7 | 3.35% |
| Hesse, Rhineland-Palatinate and Saarland | 8,120 | 8,379.8 | 11,126.4 | 3.2% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 64,960 | USD million |
| Market size 2035 | 88,295.8 | USD million |
| Revenue CAGR 2026-2035 | 3.12 | percent |
| Volume CAGR 2026-2035 | 0.7 | percent |
| Price per defined daily dose CAGR 2026-2035 | 2.4 | percent |

## Frequently asked questions

### How big is the Germany pharmaceutical drug market in 2025 and 2035?

USD 65.0 billion in 2025, from 58.0 billion daily doses at USD 1.12 each, rising to USD 88.3 billion by 2035 at a 3.12% revenue CAGR.

### Which German pharmaceutical drug segment earns most?

35.0% of 2025 value, USD 22.7 billion, comes from branded biologics, which cost about USD 26.1 per daily dose against USD 0.227 for generics.

### Which German pharmaceutical drug segment grows fastest?

9.00% a year for biosimilars, from USD 3.90 billion in 2025 to USD 9.23 billion by 2035, as antibody copies follow adalimumab.

### What does the 2026 German savings law change for drug makers?

15.5% statutory rebate from 2027 instead of 7%, a 9% extra rebate on patented vaccines and a vaccine price freeze from 1 January 2027 to 31 December 2030.

### How much does the higher rebate cost manufacturers each year?

About EUR 2.05 billion, USD 2.32 billion, a year at 2025 values, Douglas Insights estimates: 8.5 extra points on the 42% of value that carries the rebate.

### Which German state spends most on medicines?

22.0% of 2025 value, USD 14.3 billion, sits in North Rhine-Westphalia; Bavaria grows fastest at 3.45% a year.

### Who is the largest pharmaceutical seller in Germany?

5.0% of 2025 value sits with Novartis, Douglas Insights estimates; with Roche and Sanofi the top three hold only 13.4%.

### How far apart are the slower and faster 2035 cases?

USD 76.9 billion in the slower case and USD 100 billion in the faster case, against a USD 88.3 billion base.

## Sources

- [Bundesministerium für Gesundheit, Bundestag beschließt GKV-Beitragssatzstabilisierungsgesetz](https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026)
- [Bundesministerium für Gesundheit, Finanzentwicklung der GKV im 1.-4. Quartal 2025](https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/finanzentwicklung-gkv-2025)
- [Statistisches Bundesamt (Destatis), Bevölkerung Deutschlands sinkt im Jahr 2025 um 0,1 %](https://www.destatis.de/DE/Presse/Pressemitteilungen/2026/06/PD26_203_124.html)
- [Office of the United States Trade Representative, USTR announces initiation of Section 301 investigation of Germany's persistent underpayment for innovative pharmaceuticals](https://ustr.gov/about/policy-offices/press-office/press-releases/2026/june/ustr-announces-initiation-section-301-investigation-germanys-persistent-underpayment-innovative)
- [Council of the European Union, Pharma package: Council and Parliament reach a deal](https://www.consilium.europa.eu/en/press/press-releases/2025/12/11/pharma-package-council-and-parliament-reach-a-deal-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/)
- [Bayer, Bayer first quarter 2026 results](https://www.bayer.com/media/en-us/2026-0082e/)
- [Novartis, SEC, Novartis fourth quarter and full year 2025 condensed financial report](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000007/a260204-99_2.htm)
- [Boehringer Ingelheim, Geschäftsbericht Highlights 2025](https://www.bayern.landtag.de/fileadmin/lobbyregister/DEBYLT03CD/Boehringer-Ingelheim-Geschaeftsbericht-Highlights-2025.pdf)
- [STADA Arzneimittel, STADA Ergebnisse 2025](https://www.stada.de/media/5jxj24un/20260318_pressemitte-ergebnisse-2025.pdf)
- [Bank of Finland (ECB reference rates), Average annual exchange rates for the year 2025](https://www.suomenpankki.fi/en/statistics/interest-rates-and-exchange-rates/exchange-rates/average-annual-exchange-rates-for-the-year-2025/)

## How to cite

Douglas Insights, "Germany Pharmaceutical Drug Market", DI-HC-10762, updated 2026-10-23, https://www.douglasinsights.com/germany-pharmaceutical-drug-market/